Colocalization of vitiligo and alopecia areata presenting as poliosis

Walker, Addie; Mesinkovska, Natasha Atanaskova; Boncher, Julia; Tamburro, Joan; Bergfeld, Wilma F.

doi:10.1111/cup.12437

Cited by 14 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A severe disease that affects a large surface area, AT/AU pattern, long disease duration of more than one year, early onset, and associated co-morbidities have a negative effect on AA prognosis (1,15,16). Given that AA is an autoimmune disease, an association exists between AA and other conditions (17)(18)(19)(20)(21)(22)(23). Such additional co-morbidities, such as atopic and autoimmune diseases, have a diseasemodifying effect and must be included in the classification of AA and treatment plan (17).…”

Section: Discussionmentioning

confidence: 99%

Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

et al. 2021

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a tissue-specific autoimmune disease characterized by non-scarring and rapid onset of hair loss. Interleukin (IL)-17A is mainly produced by T helper 17 (Th17) cells and may play a crucial role in the pathogenesis of various autoimmune diseases including AA.Objectives: We conducted this research to measure serum level of IL-17A in patients with AA and investigated its relationship with the clinical manifestations in patients with AA.Methods: We assessed 36 patients with AA and 20 healthy control subjects. Demographic information and clinical characteristics were determined by physical examination and via the review of medical history. Serum IL-17A was measured by using enzyme-linked immunosorbent assay.Results: Serum IL-17A concentration was significantly higher in patients with AA than in the control group (P=0.004). The AA patients with severe presentation, personal atopy, nail abnormalities, or active phase had significantly higher serum IL-17A levels compared to others without these signs.Conclusion: Increased serum IL-17A levels in patients with AA correlate with severity and indicate an active disease state. These findings suggest that IL-17A may play an important role in determining the pathogenesis of AA and may serve as a valuable clinical biomarker of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Hair shaped like an exclamation mark can be present around the margins of the patch. Vitiligo and autoimmune thyroid disorders are sometimes associated with AA [86], and patchy AA often spares gray hairs [87]. …”

Section: Aa Alopecia Totalis and Alopecia Universalismentioning

confidence: 99%

Drug discovery for alopecia: gone today, hair tomorrow

Santos

Avci

Hamblin

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Hair loss or alopecia affects the majority of the population at some time in their life, and increasingly, sufferers are demanding treatment. Three main types of alopecia (androgenic [AGA], areata [AA] and chemotherapy-induced [CIA]) are very different, and have their own laboratory models and separate drug-discovery efforts. Areas covered In this article, the authors review the biology of hair, hair follicle (HF) cycling, stem cells and signaling pathways. AGA, due to dihydrotesterone, is treated by 5-α reductase inhibitors, androgen receptor blockers and ATP-sensitive potassium channel-openers. AA, which involves attack by CD8+NK group 2D-positive (NKG2D+) T cells, is treated with immunosuppressives, biologics and JAK inhibitors. Meanwhile, CIA is treated by apoptosis inhibitors, cytokines and topical immunotherapy. Expert opinion The desire to treat alopecia with an easy topical preparation is expected to grow with time, particularly with an increasing aging population. The discovery of epidermal stem cells in the HF has given new life to the search for a cure for baldness. Drug discovery efforts are being increasingly centered on these stem cells, boosting the hair cycle and reversing miniaturization of HF. Better understanding of the molecular mechanisms underlying the immune attack in AA will yield new drugs. New discoveries in HF neogenesis and low-level light therapy will undoubtedly have a role to play.

show abstract

“…On the contrary, Alopecia areata often known as spot baldness, is a medical condition, in which hair is lost from the scalp in patches 3 . It is sometimes associated with vitiligo and autoimmune thyroid conditions, often spares gray hairs 4 . It is an autoimmune condition where body's own immune system attacks own body 5 .…”

Section: Introductionmentioning

confidence: 99%

“…3 It is sometimes associated with vitiligo and autoimmune thyroid conditions, often spares gray hairs. 4 It is an autoimmune condition where body's own immune system attacks own body. 5 Later on, the body attacks its own hair follicles.…”

mentioning

confidence: 99%

Safety and efficacy of Trimax‐360 serum in healthy adult subjects with mild to moderate alopecia of scalp

Chew¹,

Gajjar

Sethi

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Male pattern baldness and female pattern baldness, commonly known as androgenic alopecia, is the most prevalent type of alopecia, often genetically predetermined. It is a condition of hair loss, which typically affects the scalp and characterized by progressive terminal hair loss. Objectives The study was conducted to evaluate efficacy and safety of botanical‐based Trimax‐360 Serum in healthy adult subjects with mild to moderate alopecia of scalp. Methods A total of 30 subjects were randomized in an open label, single arm study conducted in healthy males and females aged 30–45 years. Trimax‐360 Serum was applied twice a day for 98 days to each subject. Effect of Trimax‐360 Serum was evaluated for hair thickness, hair density, scalp condition, hair fall, hair oiliness, softness, and hair growth rate assessment. Results Statistically significant [p‐value <0.0001] improvement was observed in hair density, hair thickness, and hair growth rate after 98 days treatment with Trimax‐360 Serum. The trend of improvement in change from Baseline was gradual from Day 21 to Day 98 which was found to be 1.7%–41.5% for hair density; 0.00 µm to 10.7 µm for hair thickness, respectively. The mean (±SD) hair growth rate (μm/day) also gradually improved from 13.044(±9.4119) to 42.528(±18.5565) μm/day after 21 days to 98 days treatment with Trimax‐360 Serum. All subjects showed good scalp condition and gentle increase in noticeable new hairs while none of the patient reported hair oiliness and hair fall. No apparent adverse events were observed throughout treatment duration. Conclusions The results of this open label study suggest that 98 days treatment with botanical‐based Trimax‐360 Serum is safe and effective in significantly improving the rate of hair growth.

show abstract

Colocalization of vitiligo and alopecia areata presenting as poliosis

Cited by 14 publications

References 20 publications

Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata

Drug discovery for alopecia: gone today, hair tomorrow

Safety and efficacy of Trimax‐360 serum in healthy adult subjects with mild to moderate alopecia of scalp

Contact Info

Product

Resources

About